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166Background: Intensive insulin therapy has become a major therapeutic target in cardiac surgery patients. It has
been associated, however, with an increased risk of hypoglycemia compared with conventional insulin therapy.
Our study sought to identify the factors predisposing to hypoglycemia with intensive insulin therapy and inves-
tigate its effect on early clinical outcomes after cardiac surgery.
Methods: A concurrent cohort study of 2,538 consecutive patients undergoing cardiac surgery (coronary artery
bypass grafting, valve, or bypass grafting and valve surgery) from January 2005 to March 2010 was carried out.
Multivariable logistic regression analysis and propensity score matching were used (1) to identify the risk factors
for developing hypoglycemia (blood glucose<60 mg/dL) after cardiac surgery and (2) to compare major mor-
bidity, operative mortality, and actuarial survival between patients in whom hypoglycemia developed (n ¼ 77)
and those in whom it did not (n ¼ 2461). The propensity score–adjusted sample included 61 patients in whom
hypoglycemia developed and 305 patients in whom it did not (1 to 5 matching).
Results:Risk factors for hypoglycemia included female gender (odds ratio [OR]¼ 2.3, 95% confidence intervals
[CI]¼ 1.4–3.7; P<.001), diabetes (OR¼ 2.8, CI¼ 1.7–4.5; P<.001), hemodialysis (OR¼ 3.0, CI¼ 1.3–6.8;
P¼ .009), intraoperative blood product transfusion (OR¼ 2.0,CI¼ 1.2–3.4;P¼ .010), and earlier date of surgery
(years of surgery, 2005–2007; OR¼ 2.1, CI¼ 1.2–3.7; P¼ .007) . Hypoglycemia increased the risk for operative
mortality in univariate (hypoglycemic 10% vs normoglycemic patients 2%;P<.001) but not in propensity score–
adjusted analysis (OR¼ 2.5, 0.9–6.7;P¼ .11). The propensity score–adjusted analysis demonstrated a significant
increase in hemorrhage-related reexploration (P ¼ .048), pneumonia (P<.001), reintubation (P<.001), pro-
longed ventilatory support (P<.001), hospital length of stay (P<.001), and intensive care unit length of stay
(P<.001) for the hypoglycemic compared with normoglycemic patients. Five-year actuarial survival was similar
in the compared patient groups (hypoglycemic 75% vs normoglycemic 75%; P ¼ .22).
Conclusions: Hypoglycemia with intensive insulin therapy is independently associated with increased risk for
respiratory complications and prolonged hospital and intensive care unit lengths of stay after cardiac surgery. In
our study, hypoglycemia was not independently associated with increased risk of death. (J Thorac Cardiovasc
Surg 2011;142:166-73)Diabetes has been recognized as an independent risk factor
for the development of coronary artery disease,1 which
represents the most common cause of death in diabetic
patients.2 Diabetes is also perceived as a risk factor for ad-
verse outcomes after cardiac surgery.3-5 The Diabetes
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The Journal of Thoracic and Cardiovascular SurgInfarction (DIGAMI) study reported that glycemic control
by insulin infusions provided better long-term survival in
diabetic patients having experienced myocardial infarc-
tion.6 Other studies suggested that strict glucose control
can improve outcomes in diabetic patients undergoing
myocardial revascularization.7,8
Barriers to widespread adoption of tight glucose control
include the increased risk of severe hypoglycemia,9 the
difficulty in achieving normoglycemia in critically ill
patients,10,11 and the increased resources that would
be required.12 The Normoglycemia in Intensive Care Eval-
uation–Survival Using Glucose Algorithm Regulation
(NICE-SUGAR) trial demonstrated that intensive glucose
control increased mortality among adults in the intensive
care unit (ICU) and that a blood glucose target of 180 mg/
dL or less resulted in lower mortality than did a target of
81 to 108 mg/dL.13 The aim of our study was to identify
the factors predisposing to hypoglycemia with intensive in-
sulin therapy and to investigate its effect on clinical out-
comes after cardiac surgery.ery c July 2011
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CI ¼ confidence intervals
DIGAMI ¼ Diabetes Mellitus Insulin–
Glucose Infusion in Acute
Myocardial Infarction
ICU ¼ intensive care unit
IV ¼ intravenous
HIPAA ¼ Health Insurance Portability
and Accountability Act of 1996
NICE-SUGAR ¼ Normoglycemia in Intensive
Care Evaluation–Survival
Using Glucose Algorithm
Regulation
OR ¼ odds ratio
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Patients
The database of the Division of Cardiothoracic Surgery at the Sanger
Heart and Vascular Institute was queried and identified 2538 consecutive
patients undergoing cardiac surgery (coronary artery bypass grafting
[CABG], valve, or CABG and valve surgery) from January 2005 to
March 2010; with our glycemic control protocol, hypoglycemia devel-
oped in 77 of those patients. All patients undergoing cardiac surgery at
our institution have been receiving a protocol for insulin administration
for glycemic control. The operations were performed by the same group
of cardiac surgeons for the study period. Baseline demographics, proce-
dural data, and perioperative outcomes were recorded and entered pro-
spectively in a prespecified database by dedicated data-coordinating
personnel.
Study Design and Conduct
This is a retrospective cohort study of prospectively collected data from
consecutive patients who underwent CABG, valve, or CABG and valve
surgery at the Sanger Heart and Vascular Institute. Study approval was
sought and obtained from the Institutional Review Board. Patient confiden-
tiality was maintained at all times, consistent with the Health Insurance
Portability and Accountability Act of 1996 (HIPAA) regulations.
Glycemic Control Protocol
All patients undergoing cardiac surgery at our institution have been re-
ceiving a protocol to standardize the titration of insulin therapy during the
postoperative period. Intraoperative blood glucose levels were maintained
below 200 mg/dL with intravenous (IV) regular insulin. Glucose levels
were checked on all patients on admission to the ICU. Diabetic patients
were started on IV insulin if the serum glucose was greater than 130
gm/dL. Patients without diabetes were started on IV insulin if the serum
glucose was greater than 150 gm/dL. Euglycemia was managed with
a computerized software system (EndoTool glucose management system;
Appendix 1). This software calculates the dose of IV insulin needed. It also
actively models and adapts to individual patient responses to IV insulin—
even those with fluctuating insulin requirements (http://www.hospira.com/
Products/endotool.aspx).14 IV insulin was continued until the patient was
able to eat, whereupon the computerized algorithm generated a subcutane-
ous insulin regimen and the IV insulin was discontinued. Our glycemic
control and intensive insulin therapy protocol order set is depicted in
Appendix 1.The Journal of Thoracic and CaDefinitions
The Society of Thoracic Surgeons’ national cardiac surgery database
definitions were used for this study. Hypoglycemia after cardiac surgery
was defined as blood glucose less than 60mg/dL.Previous cerebrovascular
accident was defined as history of central neurologic deficit persisting for
more than 24 hours.Chronic renal insufficiencywas defined as a serum cre-
atinine value of 2.0 mg/dL or more. Diabetes was defined as a history of
diabetes mellitus, regardless of duration of disease or need for oral agents
or insulin. Depressed ejection fraction was defined as an ejection fraction
less than 40%.Prolonged ventilatory supportwas defined as pulmonary in-
sufficiency requiring ventilatory support for more than 24 hours postoper-
atively. Postoperative stroke was defined as any new major (type I)
neurologic deficit presenting in-hospital and persisting for more than
72 hours.15 Acute renal failurewas defined as one or both of the following:
(1) an increase in the serum creatinine to more than 2.0 mg/dL and/or
a greater than 2-fold increase in the most recent preoperative creatinine
level or (2) a new requirement for dialysis postoperatively. Prolonged
hospital length of stay was defined as hospital stay greater than 14 days.
Operative mortality includes both (1) all deaths occurring during the hos-
pitalization in which the operation was performed (even if death occurred
after 30 days from the operation) and (2) those deaths occurring after
discharge from the hospital but within 30 days of the procedure.
Data Analysis
Univariate analysis. Univariate comparisons of preoperative, oper-
ative, and postoperative variables were performed between hypoglycemic
(n ¼ 77) and normoglycemic patients (n ¼ 2461). Continuous variables
were summarized using medians and ranges; frequencies and percentages
were reported for categorical variables. Continuous variables were tested
using the Kruskal–Wallis test for association, and categorical variables
were assessed by the c2 or Fisher’s exact test, depending on the distribution
of the data. A P value of<.05 was considered statistically significant. The
Bonferroni correction was used on the postoperative outcomes (n ¼ 10).
The P value of significance was determined to be P<.005 (10 tests: .05/
10 ¼ .005).16
Multivariable analysis. Multivariable logistic regression analysis
was used to identify the risk factors for the development of hypoglycemia
and operative mortality after cardiac surgery. Predictors were chosen for
model inclusion if the univariate associations with the outcomes were
P<.1. Backward stepwise elimination was performed to keep predictors
at an alpha level< .05 for the final model.
Propensity score model. Propensity score adjustment was used to
correct for imbalances between groups at baseline and compare the postop-
erative outcomes between hypoglycemic and normoglycemic patients.17,18
A logistic regression model was fit where the hypoglycemia group was the
outcome and baseline characteristics (P<.05) from the bivariate analysis
were the covariates. Propensity scores were generated for each patient and
used to match hypoglycemic and normoglycemic patients in a nearest
neighbor fashion. The propensity score–adjusted sample included 61
patients in whom hypoglycemia developed and 305 patients who were
normoglycemic (1 to 5 matching). One to 5 matching was chosen in an
effort to improve efficiency in parameter estimation by increasing the
sample size and subsequent power. Inasmuch as there are far more
controls (nonhypoglycemic) than hypoglycemic patients, multiple
controls may be selected for each hypoglycemic patient. Using 5
controls instead of 4 increased the efficiency by 4%.19Survival Analysis
Kaplan–Meier survival estimates were calculated for the propensity
score–adjusted hypoglycemic patients and compared with the normoglyce-
mic patients using a log–rank test.
All analyses were conducted using SAS version 9.2 (SAS Institute, Inc,
Cary, NC).rdiovascular Surgery c Volume 142, Number 1 167
TABLE 1. Distribution of preoperative variables in hypoglycemic and
normoglycemic patients (univariate analysis)
Hypoglycemic
(n ¼ 77)
Normoglycemic
(n ¼ 2461)
P
value
Female gender 39 (51%) 643 (26%) <.001
Diabetes 49 (64%) 845 (34%) <.001
Congestive heart failure 22 (29%) 343 (14%) <.001
Age>75 y 12 (16%) 353 (14%) .76
Body mass index
(median/range)
29 (17–48) 28 (13–85) .87
Hypertension 66 (86%) 1949 (79%) .16
Chronic renal insufficiency 11 (14%) 97 (4%) <.001
Ejection fraction<40 25 (33%) 483 (20%) .006
Ejection fraction
(median/range)
47 (19–70) 55 (5–86) .016
Chronic Obstructive
pulmonary disease
Moderate/severe 3 (4%) 139 (6%) .80
Hemodialysis 8 (10%) 58 (3%) <.001
Acute myocardial infarction 35 (46%) 952 (39%) .23
History of stroke 9 (12%) 228 (9%) .47
Unstable angina 1 (1%) 196 (8%) .031
No. of diseased vessels
One 13 (17%) 202 (8%) .052
Two 17 (22%) 642 (26%)
Three 34 (44%) 1096 (45%)
None 13 (17%) 520 (21%)
Case priority
Elective 23 (30%) 942 (38%) .047
Urgent 45 (58%) 139 (6%)
Emergency 9 (12%) 1380 (56%)
Year of surgery
2005 14 (18%) 424 (17%) <.001
2006 14 (18%) 470 (19%)
2007 31 (40%) 510 (21%)
2008 9 (12%) 460 (19%)
2009 4 (5%) 480 (20%)
2010 5 (7%) 117 (5%)
TABLE 2. Distribution of intraoperative and postoperative variables
in hypoglycemic and normoglycemic patients (univariate analysis)
Hypoglycemic
(n ¼ 77)
Normoglycemic
(n ¼ 2461)
P
value
Intraoperative variables
CABG 60 (78%) 1896 (77%) .86
Valve surgery 28 (36%) 756 (31%) .29
Intraoperative blood
transfusion
51 (66%) 910 (37%) <.001
Crossclamp time
(median, range)
66 (19–177) 64 (15–217) .68
Crossclamp time>2 h 8 (12%) 92 (5%) .018
CPB time (median, range) 104 (16–263) 98 (23–318) .39
CPB time>2 h 26 (38%) 518 (26%) .038
Off-pump CABG 68 (88%) 1962 (80%) .064
Postoperative variables*
Hemorrhage-related
reexploration
11 (14%) 121 (4.9%) .002
Prolonged ventilatory
support (>24 h)
30 (39%) 250 (10.2%) <.001
Reintubation 19 (25%) 134 (5.4%) <.001
Pneumonia 13 (17%) 86 (3.5%) <.001
Acute renal failure 11 (14%) 101 (4.1%) <.001
Hemodialysis 4 (5%) 29 (1.2%) .016
Stroke 8 (10%) 34 (1.4%) <.001
Hospital LOS, d
(median, range)
14 (4–76) 9 (1–162) <.001
ICU LOS, d (median, range) 4.9 (1–71) 1.7 (0–105) <.001
Operative mortality 8 (10%) 60 (2%) <.001
CABG, Coronary artery bypass grafting; CPB, cardiopulmonary bypass; LOS, length
of stay; ICU, intensive care unit. *Bonferroni correction: 10 tests.05/10 ¼ .005.
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Univariate Analysis
Preoperative characteristics. Preoperative patient char-
acteristics are shown in Table 1. Hypoglycemic patients
were more likely to be female, have diabetes mellitus, con-
gestive heart failure, chronic renal insufficiency, ejection
fraction less than 40%, be on hemodialysis, and have sur-
gery during the earlier years of the study (2005–2007). Nor-
moglycemic patients were more likely to have unstable
angina than were hypoglycemic patients.
Operative and postoperative characteristics. Operative
and postoperative patient characteristics are presented in
Table 2. Because of the Bonferroni correction for postop-
erative outcomes, a P value was considered statistically
significant if it was less than .005. Hypoglycemic patients
were more likely to receive intraoperative blood products168 The Journal of Thoracic and Cardiovascular Surgthan were normoglycemic patients. Hypoglycemic patients
had a higher risk for operative mortality, hemorrhage-
related reexploration, acute renal failure, stroke, reintuba-
tion, prolonged ventilatory support, pneumonia, and
prolonged hospital and ICU lengths of stay than were
normoglycemic patients. Diabetes was associated with
a similar operative mortality both in normoglycemic pa-
tients (diabetics 3% vs nondiabetics 2%; P ¼ .23) and
in hypoglycemic patients (diabetics 14% vs nondiabetics
4%; P ¼ .25). Operative mortality was similar in patients
with blood glucose levels less than 40 mg/dL versus those
with blood glucose levels of 61 to 80 mg/dL (23% vs 8%;
P ¼ .13). Diabetes did not increase the risk of mortality in
either hypoglycemic or normoglycemic patients. Hypogly-
cemia rates were lower in the latter half of the study period
(4% for 2005–007 vs. 2% for 2008–2010; P ¼ .007).
Fifty-nine patients had 1 hypoglycemic episode, 13 had
2 episodes, 3 had 3 episodes, 1 had 5 episodes, and 1
had 8 hypoglycemic episodes. Patients who had more
than 1 episode of hypoglycemia had similar operative mor-
tality (single hypoglycemic episode 9% vs multiple epi-
sodes 17%; P ¼ .38), stroke (single hypoglycemic
episode 10% vs multiple episodes 11%; P>.99), and pro-
longed ventilatory support (single hypoglycemic episodeery c July 2011
TABLE 4. P values before and after propensity score matching
Before After
Female gender <.001 .71
Diabetes <.001 .45
Congestive heart failure .006 .82
Chronic renal insufficiency .002 .61
Ejection fraction<40 .006 .88
Chronic obstructive pulmonary disease <.001 .63
Hemodialysis <.001 .40
Unstable angina .031 >.99
Status .047 .80
Year of surgery <.001 .81
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M34% vs multiple episodes 56%; P ¼ .17) compared with
those who had multiple hypoglycemic episodes. ICU
length of stay was more abbreviated, however, in patients
with single compared with multiple episodes of hypogly-
cemia (single hypoglycemic episode median ICU stay
4.5 days, range ¼ 1–57 days, vs multiple episodes median
ICU stay 8 days, range ¼ 1–71 days; P ¼ .03). Hospital
length of stay, however, was similar between the patients
who had a single hypoglycemic episodes versus those
who had multiple episodes (single hypoglycemic episode
median hospital stay 14 days, range ¼ 4–65 days, vs mul-
tiple episodes median hospital stay 14 days, range ¼ 5–76
days; P ¼ .49).
Multivariable Logistic Regression Analysis
Female gender (odds ratio [OR] ¼ 2.3, 95% confidence
intervals [CI] ¼ 1.4-3.7; P< .001), diabetes (OR ¼ 2.8,
CI ¼ 1.7–4.5; P < .001), hemodialysis (OR ¼ 3.0,
CI¼ 1.3–6.8; P¼ .009), intraoperative blood product trans-
fusion (OR¼ 2.0, CI¼ 1.2–3.4; P¼ .010), and earlier date
of surgery (year of surgery 2005–2007 OR ¼ 2.1,
CI¼ 1.2–3.7; P¼ .007) emerged as independent predictors
of hypoglycemia after cardiac surgery. TheC statistic for the
model was 74%, which indicates a good fit. Hypoglycemia
was also identified as an independent predictor of mortality
in the multivariate logistic regression analysis (OR ¼ 2.7,
95% CI ¼ 1.1–6.3; P ¼ .027, C statistic ¼ 76%; Table 3).
Propensity score analysis. The ability of the propensity
score to effectively balance the groups at baseline was con-
firmed by showing that the variables put into the propensity
score were no longer significant in the matched sample
(Table 4). Hence, the groups were more balanced for the
subsequent testing of outcomes in the matched samples.
Results of the propensity score–adjusted analysis are
depicted in Table 5. Another Bonferroni correction was
done so that P values< .005 were considered statistically
significant. The propensity score–adjusted OR demon-
strated a significant increase in hemorrhage-related reexplo-
ration (P ¼ .0048), pneumonia (P< .001), reintubation
(P<.001), prolonged ventilatory support (P<.001), and
prolonged hospital (P < .001) and ICU lengths of stayTABLE 3. Multivariable logistic regression analysis model of
operative mortality
Beta SD OR 95% CI P value
Hypoglycemia .49 .22 2.7 1.1–6.3 .027
Diabetes .31 .14 1.9 1.1–3.2 .021
Congestive heart failure .45 .14 2.4 1.4–4.3 .002
Age>75 y .54 .14 3.0 1.7–5.1 <.001
Valve surgery .32 .14 1.9 1.1–3.4 .023
Case priority
Elective vs urgent .61 .21 0.8 0.4–1.5 .003
Emergency vs urgent 1.02 .23 4.2 2.1–8.3 <.001
SD, Standard deviation; OR, odds ratio; CI, confidence intervals. C statistic ¼ 76%
The Journal of Thoracic and Ca
P(P<.001) for the hypoglycemic compared with the normo-
glycemic patients. Propensity score adjustment also showed
a similar mortality for hypoglycemic compared with
normoglycemic patients (P ¼ .11).
Survival analysis. Kaplan–Meier survival estimates are
presented in Figure 1. There was no difference in the
actuarial 5-year survival between hypoglycemic and nor-
moglycemic patients in the propensity score–matched pop-
ulation. Specifically, actuarial 5-year survival was 75% for
hypoglycemic patients versus 75% for normoglycemic pa-
tients (Figure 1).
DISCUSSION
Intensive insulin therapy has become a standard modality
in patients undergoing cardiac surgery. Previous studies re-
ported that strict glycemic control with intensive insulin
therapy may improve outcomes after cardiac surgery,20
and others reported increased mortality with intensive insu-
lin therapy among adults in the ICU.13,21 Specifically
according to the NICE-SUGAR study, intensive glucose
control with a blood glucose target of 180 mg/dL resulted
in higher mortality than did a target blood glucose of 180
mg/dL or less. Among other risks, intensive insulin therapy
has been associated with increased risk of severe hypogly-
cemia. Randomized controlled trials of intensive insulin
therapy reported variable frequency of hypoglycemic epi-
sodes ranging between 5% and 32% of patients treated
with intensive insulin therapy compared with 0.8% to 5%
in patients treated with conventional insulin therapy proto-
cols.22-24 Differences in hypoglycemia rates with intensive
insulin therapy may be related to different protocols,
different proportions of diabetic patients, and different
patient populations. The effect of hypoglycemia after
cardiac surgery has not been thoroughly investigated. Our
study identified the factors predisposing to hypoglycemia
with intensive insulin therapy and evaluated the effect of
hypoglycemia on clinical outcomes after cardiac surgery.
Principal Findings
Hypoglycemic patients experience greater morbidity and
similar operative mortality compared with normoglycemicrdiovascular Surgery c Volume 142, Number 1 169
TABLE 5. Adjusted by propensity score ORs for early hospital outcomes in normoglycemic and hypoglycemic patient groups
Hypoglycemic
(n ¼ 61)
Normoglycemic
(n ¼ 305) OR 95% CI
P
value
Hemorrhage-related reexploration 10 (16%) 16 (5%) 3.5 1.5–8.2 .0048
Acute renal failure 10 (16%) 20 (7%) 2.8 1.2–6.3 .011
Hemodialysis 4 (7%) 6 (2%) 3.5 1.0–12.8 .067
Stroke 6 (10%) 9 (3%) 3.6 1.2–10.5 .025
Hospital LOS, d (median, range) 20 (4-76) 9 (3-134) NA <.001
ICU LOS, d (median, range) 5 (171) 2 (0–77) NA <.001
Reintubation 14 (23%) 19 (6%) 4.5 2.1–9.6 <.001
Prolonged ventilatory support (>24 h) 23 (38%) 35 (12%) 4.7 2.5–8.7 <.001
Pneumonia 10 (16%) 9 (3%) 6.5 2.5–16.7 <.001
Operative mortality 6 (10%) 13 (4%) 2.5 0.9–6.7 .11
OR, Odds ratio; CI, confidence intervals; LOS, length of stay; ICU, intensive care unit; NA, not available. Bonferroni correction: 10 tests.05/10 ¼ .005.
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Mpatients after cardiac surgery, after adjusting for imbalances
in the preoperative risk factors and using a stringent testing
criterion (the Bonferroni correction), a finding that agrees
with previous studies.24 When adjusted for potential con-
founders, hypoglycemia was not associated with increased
mortality, which contradicts previous studies. Specifically,
according to the NICE-SUGAR trial, intensive glucose con-
trol increased mortality among adults in the ICU, and
a blood glucose target of 180mg/dL or less resulted in lower
mortality than did a target of 81 to 108 mg/dL.13 Similarly,
Hermanides and associates21 demonstrated an increased
mortality with blood glucose levels below 45 mg/dL in
the ICU. However, these 2 studies did not focus on the
cardiac surgery population and used different definitions
for hypoglycemia than did our study.
Hypoglycemia and Postoperative Complications
We demonstrated that hypoglycemia was associated with
a higher rate of hemorrhage-related reexploration, pro-FIGURE 1. Freedom from death at 5 years. Kaplan–Meier survival estimates i
log–rank test, is reported.
170 The Journal of Thoracic and Cardiovascular Surglonged ventilatory support, reintubation, pneumonia, and
prolonged hospital and ICU lengths of stay. The surgical
stress and the adrenergic response associated with it may
explain the higher frequency of hypoglycemic episodes in
patients who had hemorrhage-related reexploration.
Hypoglycemia may contribute to postoperative stroke by
inducing neuroglycopenia with neuronal cell loss and hypo-
glycemic coma, especially after hyperglycemic reperfu-
sion.21 Furthermore, hypoglycemia might provoke
ischemia in pre-existing vascular disease in patients with
diabetes25 and it has also been shown to induce platelet
activation and inflammation in an experimental setting.26
Hypoglycemia could thus contribute to acute renal failure,
respiratory complications, and prolonged hospital length
of stay by aggravating overall illness.21 Hypoglycemia
was more frequent in diabetic patients, possibly because
of a wider fluctuation of blood glucose levels, a more unpre-
dictable response to the infused insulin, as well as a higher
interindividual variability in the diabetic versus then the propensity score–adjusted patient groups. P value, calculated with the
ery c July 2011
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Mnondiabetic patients.27 The lower rate of hypoglycemia in
the latter half of the study period may be attributed to em-
ployment of a rigorous quality improvement protocol in
our institution that also resulted in a decrease in operative
mortality, as we28 previously reported.
Single hypoglycemic episodes were associated with sim-
ilar mortality and postoperativemorbidity but a more abbre-
viated ICU length of stay compared with those in patients
who had multiple hypoglycemic episodes.
Actuarial Survival
Our study demonstrated a similar actuarial 5-year
survival in hypoglycemic and normoglycemic patients
(log–rank P¼ .22, Figure 1). As depicted in Figure 1, there
was an initial survival difference secondary to a higher early
mortality for the hypoglycemic compared with the normo-
glycemic patients; however, at 5 years the 2 curves touch
each other, reflecting a similar 5-year survival.
Clinical Implications
In this study we used a real-world unselected cohort of
patients with prospectively acquired data by dedicated data
management personnel to compare early hospital out-
comes between hypoglycemic and normoglycemic patient
groups and to evaluate the risk factors for hypoglycemia
after cardiac surgery. On the basis of our results, hypogly-
cemic patients had a higher operative mortality as well as
a higher rate of hemorrhage-related reexploration, pro-
longed ventilatory support, reintubation, pneumonia, and
prolonged hospital and ICU lengths of stay than normogly-
cemic patients in univariate analysis. After propensity
score adjustment, operative mortality was similar, but the
respiratory complications and hemorrhage-related reexplo-
ration rates were higher and hospital and ICU lengths of
stay were more prolonged in the hypoglycemic patients
than in the normoglycemic patients. Our study also
showed a similar actuarial 5-year survival for hypoglyce-
mic compared with normoglycemic patients. Among the
factors found to increase the risk of hypoglycemia (female
gender, diabetes, hemodialysis, intraoperative blood trans-
fusions) after cardiac surgery, only intraoperative blood
transfusion is amenable to therapeutic intervention. A
higher target level of blood glucose in the postoperative
period may decrease the frequency of hypoglycemic epi-
sodes and thus reduce the rates of complications associated
with it. A more focused and individualized approach may
be warranted for diabetics, women, and patients with renal
failure and should stimulate future studies. Future studies
may also be warranted to evaluate the optimal goal of
blood glucose levels after cardiac surgery, at which im-
proved outcomes are achieved without significant hypo-
glycemic risk. Prospective randomized studies may help
to better define strategies, benefits, and risks of intensive
insulin therapy.The Journal of Thoracic and CaSTUDY LIMITATIONS
Limitations of this study include all those inherent in any
retrospective, single-institution analysis. This was a non-
randomized study in which unmeasured patient- or
procedure-related variables may have influenced the study
results. Furthermore, this investigation was conducted at
a large tertiary referral center, and the results may not be
broadly representative of community practice. Another lim-
itation of our study was the small number of the hypoglyce-
mic patient group, which may have prevented us from
demonstrating a difference in mortality secondary to
a type II error. There are also several known and unknown
variables such as steroid use, discontinuation of catechol-
amines, and others that were not adjusted for in the propen-
sity score–adjusted multivariable analysis. Our study did
not compare different insulin therapy protocols to identify
one that best achieves the glycemic targets associated
with the lowest hypoglycemia risk. Evaluation of the effects
of hypoglycemia variability and hypoglycemia temporal
trends on the postoperative outcome was beyond the scope
of our study. Moreover, the level of 60 mg/dL is not neces-
sarily an accurate marker of hypoglycemia inasmuch as
hormonal imbalance may present at even higher levels of
blood glucose. The ranges, averages, and median glucose
values were not available to us during the study period
and will be the focus of future investigations by our institu-
tion. Among the strengths of this study are the large cohort
of patients, the prospective entry of all data elements into
a cardiac surgical research database with strict definitions,
and analysis of data performed with appropriately
risk-adjusted statistical models to adjust for differences in
preoperative risk factors.
In conclusion, hypoglycemic patients had a similar oper-
ative mortality and 5-year actuarial survival and a higher
rate of postoperative respiratory complications and
prolonged hospital and ICU lengths of stay than did normo-
glycemic patients. Actuarial 5-year survival was similar in
the 2 patient groups.References
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Carolinas Medical Center (CMC)
Tight Blood Glucose Control Orders for Adult Patient in M
(Target 80–120 gm/dL)
EndoTool Program
CMC Medical Executive Committee
Implement STANDING Physician order: SO CMC Tight
STICU, DHICU, CVRU, or NSICU
Verify Allergies
Inclusion Criteria: Adult patient in MICU, STICU, DHICU
known diabetic or nondiabetic patient and is receiving steady
dextrose solutions, steady tube feedings, or TPN.
Exclusion Criteria: Do not use this order set to manage a pa
the attending physician. Contact MD for alternative blood gluc
mittent tube feedings.
Pharmacy
250 units regular insulin in 250 mL normal saline (NS)
Dextrose 50% IV PRN per EndoTool Program
Note: Mix all IV medications in NS or ½ NS when possibl
If an IV insulin infusion is started for tight glucose control
ing scale, continuous infusion, and/or scheduled bolus do
Nursing
Check blood glucose via finger stick or laboratory (BMP, CM
and/or changes in vital signs, neurologic status, or nutriti
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Blood Glucose Control Orders for Adult Patient in MICU,
, CVRU, or NSICU who meets clinical criteria below for
nutritional support. This nutrition can be steady IVs with
tient with diabetic ketoacidosis (DKA) unless approved by
ose control measures if patient is eating or receiving inter-
e
: discontinue all current insulin orders, including PRN, slid-
ses.
P, or glucose) upon arrival to unit and PRN for symptoms
on status.
ery c July 2011
For known Diabetic Patient:
(a) If glucose is greater than 130 gm/dL: initiate insulin infusion according to Insulin Infusion Orders below
(b) If glucose is 130 gm/dL or less: check glucose Q6H. Initiate Insulin Infusion Orders below if any blood glucose is
greater than 130 gm/dL.
For Nondiabetic Patient:
(a) If glucose is greater than 150 gm/dL: initiate insulin infusion according to Insulin Infusion Orders below.
(b) If glucose is 150 gm/dL or less: check glucose every AM. Initiate Insulin Infusion Orders below if any blood glucose is
greater than 150 gm/dL.
When blood glucose is stable for 24 hours, request specific insulin order from physician
Prior to starting the infusion, waste approximately 30 mL of the insulin mixture through the IV tubing to saturate the
plastic tubing with insulin.
INSULIN INFUSION ORDERS
The patient must be on steady nutritional support to be eligible for EndoTool insulin dose calculations. This nutrition can
be steady IVs with dextrose solutions, steady tube feedings, or TPN. Alternative blood glucose control measures must be
used if the patient is eating or receiving intermittent tube feedings. Titration of the TPN or titration of the tube feeding
or titration of clear liquids is allowed with the EndoTool protocol.
Start the EndoTool Program by entering the necessary patient information into the computer.
If patient is currently on the EndoTool Program and is transferring from another intensive care unit: enter the ‘‘BR’’ and
‘‘f’’ factors if known.
If patient is transferring from a nonintensive care unit: search for the patient by medical record number in the inactive file
by clicking on the View inactive patient’s link under the System Tasks heading.
Follow EndoTool Program instructions for insulin infusion rates, bolus doses, D50W doses, and blood glucose
determination frequency. For glucose levels of 80 mg/dL or less: the insulin infusion is zero (0.0) or OFF.
Nurse must obtain a physician order to give any dose that is not the calculated dose.
Use a micropump for insulin infusion and attach into a ‘‘Y’’ site as close to where the IV is inserted into the patient as
possible with compatible IV fluids that infuse at a constant rate of at least 30 mL/h.
Insert Daily Summary Report and Order Sheet generated by EndoTool Program each morning into the patient’s chart for
documentation of the glucose readings and insulin doses administered.
If the patient is on TPN or tube feeding that is interrupted for more than 30 minutes while on the insulin infusion: run
D10W IV at the same rate as the interrupted TPN or tube feeding rate. (Must have OK from Neurosurgery if
Neurosurgery is attending or consulting). Check glucose Q1H after a change in nutrition status and PRN.
STOPPING EndoTool PROGRAM
Discontinue EndoTool Program once the patient is allowed to eat and contact the primary physician regarding further
orders for blood glucose management.
Patient on EndoTool programwho has resumed oral intake: Print the Patient-specific SubQ insulin orders fromEndoTool for
SubQ insulin coverage. Leave IV insulin drip running for 2 hours after first dose of SubQ lantus insulin given.
Stop insulin drip once alternative diabetic treatment is ordered and started.
‘‘IV Insulin Drip Orders’’ option may be printed with a physician order and used if the patient is ordered to remain on an
insulin drip and is being transferred to another critical care unit.
Print the last MAR/Orders from the ‘‘Print Patient Reports/Orders’’ option and place in the patient’s chart.
If the patient is transferring out of current room: click on the Patient Information tab and change the patient’s status to
inactive’’ by changing the ‘‘Active’’ status from ‘‘Y’’ to ‘‘N.’’ Click ‘‘Save & Continue’’ to save the information.
DATE: ______ TIME: ______ RN SIGNATURE: __________________________
(RN implementing Standing order)
DATE: _______ TIME: _______ MD SIGNATURE: _________________________
Official Use only: Approved by CMC Medical Executive Committee(s) Approval Date:_______________
(May 2008)
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